GH Research (NASDAQ:GHRS) Sees Unusually-High Trading Volume - What's Next?

GH Research PLC (NASDAQ:GHRS - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 141,029 shares changed hands during trading, a decline of 15% from the previous session's volume of 165,108 shares.The stock last traded at $10.61 and had previously closed at $10.76.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GHRS. Stifel Nicolaus increased their price objective on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Guggenheim began coverage on GH Research in a report on Thursday, March 13th. They set a "buy" rating and a $32.00 target price on the stock. Royal Bank of Canada initiated coverage on GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of GH Research in a research note on Thursday, February 13th. They set an "overweight" rating and a $14.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, GH Research presently has an average rating of "Buy" and a consensus target price of $30.86.

GH Research Price Performance

The stock's 50 day simple moving average is $11.92 and its 200-day simple moving average is $9.43. The company has a market capitalization of $484.90 million, a PE ratio of -11.80 and a beta of 0.84.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. On average, equities analysts predict that GH Research PLC will post -0.8 earnings per share for the current year.

Hedge Funds Weigh In On GH Research

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Lynx1 Capital Management LP grew its holdings in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Diadema Partners LP purchased a new position in GH Research in the fourth quarter valued at $711,000. Woodline Partners LP raised its stake in GH Research by 112.0% in the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after buying an additional 41,711 shares in the last quarter. Geode Capital Management LLC lifted its holdings in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after buying an additional 3,092 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after acquiring an additional 8,641 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).